Publications by authors named "K K Ojo"
is a common, waterborne gastrointestinal parasite that causes diarrheal disease worldwide. Currently there are no effective therapeutics to treat cryptosporidiosis in at-risk populations. Since natural products are a known source of anti-parasitic compounds, we screened a library of extracts and pure natural product compounds isolated from bacteria and fungi collected from subterranean environments for activity against .
View Article and Find Full Text PDFTreatment with BKI-1748 after systemic dissemination in experimentally infected pregnant sheep improves fetal and lamb mortality and morbidity and prevents congenital infection.
Roberto Sánchez-Sánchez Ana Huertas-López Andrea Largo-de la Torre Ignacio Ferre Filippo Maria Dini Kayode K Ojo
Antimicrob Agents Chemother
February 2025
Article Synopsis
- Drug development for congenital toxoplasmosis is challenging due to high adverse effects and poor efficacy of first-line therapies; bumped kinase inhibitors (BKIs) like BKI-1748 may offer a new treatment option.
- In a study involving 19 pregnant sheep, those treated with BKI-1748 after infection showed lower fever and immunological responses compared to untreated counterparts.
- The treated group had a higher percentage of healthy lambs at delivery and showed no evidence of congenital transmission of the parasite, unlike the untreated group where parasite DNA was detectable.
Article Synopsis
- Metastatic castration-resistant prostate cancer is still incurable, despite recent treatments, and tumors show increased glycolysis as they progress.
- The study introduces BKIDC-1553, a new small-molecule compound that inhibits glycolysis specifically in prostate cancer cells without causing severe toxicity, and demonstrates promising results in preclinical models.
- BKIDC-1553 shows effective growth inhibition in various prostate cancer models and has safety and pharmacokinetic properties that suggest it’s ready for clinical trials to treat advanced prostate cancer.